DE60228419D1 - Hemmung der atf2-aktivität zur behandlung von krebs - Google Patents

Hemmung der atf2-aktivität zur behandlung von krebs

Info

Publication number
DE60228419D1
DE60228419D1 DE60228419T DE60228419T DE60228419D1 DE 60228419 D1 DE60228419 D1 DE 60228419D1 DE 60228419 T DE60228419 T DE 60228419T DE 60228419 T DE60228419 T DE 60228419T DE 60228419 D1 DE60228419 D1 DE 60228419D1
Authority
DE
Germany
Prior art keywords
therapies
atf2
cancer
inhibition
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60228419T
Other languages
English (en)
Inventor
Ev Ronai Ze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Application granted granted Critical
Publication of DE60228419D1 publication Critical patent/DE60228419D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DE60228419T 2001-02-15 2002-02-14 Hemmung der atf2-aktivität zur behandlung von krebs Expired - Fee Related DE60228419D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26911801P 2001-02-15 2001-02-15
US26925701P 2001-02-16 2001-02-16
PCT/US2002/005215 WO2002064025A2 (en) 2001-02-15 2002-02-14 Inhibition of atf2 activity to treat cancer

Publications (1)

Publication Number Publication Date
DE60228419D1 true DE60228419D1 (de) 2008-10-02

Family

ID=26953513

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60228419T Expired - Fee Related DE60228419D1 (de) 2001-02-15 2002-02-14 Hemmung der atf2-aktivität zur behandlung von krebs

Country Status (6)

Country Link
US (2) US7314855B2 (de)
EP (1) EP1368049B1 (de)
AT (1) ATE405283T1 (de)
AU (1) AU2002242214A1 (de)
DE (1) DE60228419D1 (de)
WO (1) WO2002064025A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064785A2 (en) * 2003-01-14 2004-08-05 Dana Farber Cancer Institute Cancer therapy sensitizer
CA2595669A1 (en) * 2004-10-18 2006-04-27 Mount Sinai School Of Medicine Of New York University Inhibition of tumor growth and metastasis by atf2-derived peptides
US7408022B2 (en) * 2004-11-09 2008-08-05 Celtek Bioscience, Llc Composition and method for increasing apoptosis in cancer cells
US7776894B2 (en) * 2007-08-17 2010-08-17 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
WO2011041494A1 (en) * 2009-09-30 2011-04-07 Baylor College Of Medicine Tex14 peptides as novel antitumor agents
US9029340B2 (en) 2010-07-22 2015-05-12 The Johns Hopkins University Radiation sensitization agents for prostate cancer
US20120095078A1 (en) * 2010-10-07 2012-04-19 Sanford-Burnham Medical Research Institute Methods of diagnosis and treatment of melanoma
CN106420712B (zh) * 2015-08-10 2020-09-25 上海市中医老年医学研究所 茴香霉素在制备预防/治疗卵巢癌药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736381A (en) 1995-05-19 1998-04-07 Davis; Roger J. Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
JP2002502394A (ja) * 1997-05-28 2002-01-22 メルコラ，ダニエル，エー． ストレス活性化プロテインキナーゼ（ｓａｐｋ）経路の阻害及び癌療法に対する細胞の増感
US6022952A (en) * 1998-04-01 2000-02-08 University Of Alberta Compositions and methods for protein secretion

Also Published As

Publication number Publication date
US7935525B2 (en) 2011-05-03
US7314855B2 (en) 2008-01-01
ATE405283T1 (de) 2008-09-15
AU2002242214A1 (en) 2002-08-28
EP1368049A2 (de) 2003-12-10
EP1368049A4 (de) 2004-09-08
US20020169121A1 (en) 2002-11-14
WO2002064025A3 (en) 2002-12-19
WO2002064025A2 (en) 2002-08-22
US20080139475A1 (en) 2008-06-12
EP1368049B1 (de) 2008-08-20

Similar Documents

Publication Publication Date Title
NO20040222L (no) Peptider til fjerning eller destruksjon av celler
WO2003089456A3 (en) Peptide inhibitors of protein kinase c
WO2006090810A3 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
MX2008009493A (es) Peptido novedoso y uso del mismo.
DE60228419D1 (de) Hemmung der atf2-aktivität zur behandlung von krebs
HK1128924A1 (en) Sparc-derived cancer rejection antigen peptide and pharmaceutical comprising the same sparc
ATE488529T1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
CY1110381T1 (el) Πεπτιδια χ-κωνοτοξινης ως αναστολεις των νευρωνικων αμινικων μεταφορεων
DE60041989D1 (de) P21-peptide zur hemmung von cdk/cyclin-komplexen
HK1052026A1 (en) Human enzymes of the metalloprotease family
BR112022012057A2 (pt) Novos métodos de entrega celular
WO2005123760A3 (en) Treating cancer
ATE362768T1 (de) Prb2/p130 peptidinhibitoren der cdk2 kinaseaktivität
MXPA05008535A (es) Identificacion y caracterizacion de racemasas, definicion de firmas proteinicas, y una prueba para examinar aminoacido d para seleccionar moleculas capaces de inhibir la actividad de racemasa, especialmente racemasa de prolina.
EP2343311A3 (de) Peptidinhibitoren von HK2 und deren Anwendung
Kariya et al. Inhibition of angiotensin converting enzyme of rat brain with bradykinin and its fragments
SE9700301D0 (sv) New compound
WO2021062389A3 (en) Peptide for treating cancer
DE60314289D1 (de) Synthetische peptidanaloge zur behandlung von krebs
ATE363536T1 (de) Verfahren und zusammenstzung zur hemmung des wachtums von neoplastischen zellen
ATE295963T1 (de) Zusammensetzungen sowie verfahren zur diagnose und behandlung von tumorerkrankungen
ATE393162T1 (de) Transkriptionsfaktor-e2f-dna-bindungsdomäne hemmende peptide und ihre verwendung
HK1083850A1 (en) Peptides binding the phosphatase 2a protein and polynucleotides encoding same
WO2007129999A3 (en) Antiproliferative peptides and antibodies for their detection
MX2024009427A (es) Fragmento c-terminal de apolipoproteina e y aplicacion del mismo en la inhibicion de la actividad de \03b3-secretasa.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee